Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.

Antimicrobials and AMR

The Antimicrobials and AMR team unites Liverpool’s strengths in clinical pharmacology, therapeutics, data sciences and population health to address the global threat posed by antimicrobial resistance (AMR).

Antimicrobial therapy underpins almost all complex medical interventions. Antimicrobial resistance (AMR) threatens human, animal, and environmental health and is recognised as one of the most urgent global health threats. Annually, an estimated 4.95 million deaths are associated with AMR.

The UN General Assembly has called for urgent, coordinated international efforts to promote the responsible use of antimicrobials, boost research and development for new drugs, vaccines, and diagnostics, and strengthen global surveillance. 

At the University of Liverpool, we lead the Centres for Antimicrobial Optimisation Network (CAMO-Net), a Wellcome-funded multidisciplinary global collaborative research network focused on addressing the impact of antimicrobial resistance on human health.

We are also a host institution for the Fleming Fund Fellowship Scheme, offering mentorship and training to professionals engaged in antimicrobial resistance from Nigeria and Sierra Leone.

  • Led by Professor William Hope, the group uses pharmacodynamic, pharmacometric and data science approaches to develop new therapeutic strategies to tackle infection and antimicrobial resistance.

  • Led by Professor Shampa Das, the APT Accelerator supports industry to develop new antibiotics and other antimicrobial agents to address unmet medical needs related to antimicrobial resistance.

  • Led by Professor Alison Holmes, the group is focused on tackling antimicrobial resistance and playing a pivotal role in developing strategies to manage infectious diseases around the world.

  • Find out more about the Antimicrobials and AMR team.